Please login to the form below

Not currently logged in
Email:
Password:

QALY

This page shows the latest QALY news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s Halaven

NICE set to reject wider use of Eisai’s Halaven

Halaven costs £361 or £541.50 per vial - depending on dose - and NICE estimates that its cost-effectiveness range from £36, 244 to £82, 743 per quality-adjusted life year (QALY).

Latest news

More from news
Approximately 2 fully matching, plus 106 partially matching documents found.

Latest Intelligence

  • Medical education

    Healthcare terms - Medical education.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    weighting criteria needed to allow for a higher cost per QALY.”Managed entry agreements are still likely to be needed. ... A NICE spokesperson told PME: “These drugs will now be evaluated against a sliding scale, so that the more additional QALYs a

  • Japanese pharma pulls no punches with post-Brexit UK Japanese pharma pulls no punches with post-Brexit UK

    Calling for quality-adjusted life year (QALY) thresholds to be “set to realistic levels”, the JPG believes there is a need for a “mindset change”at NICE that leads to “more

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    The hypothetical therapy gave up to 10 additional quality-adjusted life years (QALYs), representing a 10-year life extension at full health. ... The price for the bridging therapy was set at £356, 100 for a QALY gain of 7.46 and £528, 000 for the

  • Communicating value Communicating value

    HTA is the preferred tool to determine value, but true value goes beyond the algorithms, QALYs, and ICERs, which seek to justify price.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Tracking comms trends: communication and market access

    Measures like progression-free survival and cost per QALY are not easy concepts to convey to the non-medically trained. ... The real challenge lies in finding a better approach, while avoiding the QALY, to bring additional clarity into the discussion of

  • Tracking comms trends: communication and market access

    Measures like progression-free survival and cost per QALY are not easy concepts to convey to the non-medically trained. ... The real challenge lies in finding a better approach, while avoiding the QALY, to bring additional clarity into the discussion of

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics